Tag : MEAN MONTHLY MIGRAINE DAYS

CONFERENCE UPDATE

Atogepant demonstrates superior efficacy and tolerability vs. topiramate in migraine prevention: Results from the head-to-head TEMPLE trial
In the phase 3b TEMPLE trial, atogepant demonstrated superior efficacy and tolerability vs. topiramate for migraine prevention. Atogepant also showed fewer treatment discontinuations due to adverse events, greater reductions in monthly migraine days, and higher rates of ≥50% reduction in migraine frequency, while maintaining a favorable safety profile.